Small cell lung cancer

Start here

Small cell lung cancer at a glance

Small cell lung cancer (SCLC) is a fast-growing lung cancer that often responds well to initial treatment. Prompt assessment is important. Your team needs to confirm the diagnosis, find out how far the cancer has spread (its stage), and check which treatments you can safely receive.

Limited-stage SCLC can fit within a chest radiotherapy plan intended to treat all the cancer safely. Radiotherapy uses radiation to destroy cancer cells. Some limited-stage cancers can be treated with the aim of cure. Extensive-stage SCLC has spread beyond this extent and is usually treated to control the cancer, help people live longer and relieve symptoms. The staging diagram below explains the distinction in more detail.

This guide is separate from non-small cell lung cancer (NSCLC) because the two types behave differently and need different treatments. SCLC is called a high-grade neuroendocrine cancer: its cells grow quickly and have features of cells that receive nerve signals and release hormones, the body's chemical messengers. It differs from slower-growing lung neuroendocrine tumours called typical and atypical carcinoids. A specialist review of the tissue confirms which type you have.

The first treatment can shrink SCLC substantially. Follow-up remains important because the cancer can come back; this is called recurrence.

Symptoms and warning signs

Symptoms can include a persistent cough, breathlessness, coughing blood, chest discomfort, repeated chest infections, weight loss and fatigue (tiredness or lack of energy). Some people develop symptoms from cancer outside the chest or from hormones produced by the cancer. Scans and a biopsy, which takes a small tissue sample for examination, help distinguish SCLC from other causes.

Severe breathlessness, substantial coughing of blood, collapse or chest pain needs emergency assessment. Swelling of the face or neck with breathing difficulty may mean that cancer is pressing on the large vein draining the upper body. A new severe headache, a seizure (a fit), confusion, weakness or difficulty walking also needs urgent attention. Rapidly worsening symptoms should not wait for the next clinic visit.

Making this information useful to you

A cancer diagnosis can arrive before you have had time to understand the tests. You do not need to learn every treatment name at once. Begin with the exact diagnosis, where the cancer is, and what the team recommends next. A relative or friend can join the appointment if you would find that helpful.

This guide explains possibilities, not a prescription for your situation. Your tissue test results, scans, general health, previous treatment and priorities determine which possibilities apply. Two people with the same cancer name may appropriately receive different treatment. If a recommendation differs from something you have read, ask the team to explain the reason and the evidence behind it.

Keep a list of medicines, allergies and other health conditions, including non-prescription products, vitamins and herbal remedies. Tell the team about previous cancer treatment, pregnancy or breastfeeding, and anything that could affect attending appointments. Do not stop an established medicine without advice. Bring your questions in the order that matters most to you, so that the most important concern is discussed first.

Understand

How small cell lung cancer behaves

SCLC can spread early through the bloodstream and lymph nodes, small structures that are part of the immune system. It may reach the liver, bones, brain or adrenal glands, which make hormones and sit above the kidneys. This is why medicines that reach cancer throughout the body are important even when the tumour looks small. Surgery or radiotherapy to one area is usually only one part of a combined treatment plan.

Most cases are linked to tobacco exposure. People deserve care and support without blame. Stopping smoking after diagnosis can help general health and the ability to cope with treatment. Ask for help with cravings, withdrawal symptoms and medicines that can help you stop. Family members can support a smoke-free home and share the practical effort.

Effects of hormones and the immune system

SCLC can sometimes cause symptoms away from the tumour through hormones or changes in the immune system. These are called paraneoplastic syndromes. Examples include:

• Low blood sodium: too much antidiuretic hormone, which controls the body's water balance, can make the body hold on to water and lower the sodium level. Symptoms can include nausea, headache, confusion or seizures.
• Too much cortisol: some cancers make adrenocorticotropic hormone (ACTH). This causes the adrenal glands to make too much cortisol, a stress hormone. It can cause weakness, high blood pressure, high blood sugar, low potassium or infections.
• Muscle weakness: an immune reaction can interfere with signals between nerves and muscles. One example is Lambert–Eaton myasthenic syndrome.

These problems need assessment alongside cancer treatment. Do not try to treat a low sodium result by drinking large amounts of water or taking salt tablets: the right treatment depends on the cause and severity. Marked confusion, a seizure or sudden severe weakness is an emergency. Treating the cancer may help these syndromes, but additional treatment is often needed.

Tests and diagnosis

How cancer is diagnosed

The team chooses a safe way to collect a tissue or cell sample. This may also help establish the stage. Options include:

• Bronchoscopy: a thin camera tube passes into the airways so that the doctor can examine them and take samples.
• Endobronchial ultrasound (EBUS): a probe on the camera tube uses sound waves to show nearby structures and guide a needle into lymph nodes in the chest.
• Needle biopsy: a needle takes a sample from the lung or another accessible area, often guided by a scan.
• A fluid sample: if fluid has collected around the lung, testing it may help identify cancer cells.

A pathologist, a doctor who examines tissue and cells, uses a microscope and special laboratory stains to identify the cancer. Some tumours contain both small cell and non-small cell areas. Occasionally, a previously treated NSCLC changes into SCLC; a new biopsy can identify this change, called transformation. Tissue or cell testing is usually needed to confirm SCLC when a sample can be obtained safely.

Scans and blood tests

Different scans answer different questions:

• Computed tomography (CT) uses X-rays to make detailed pictures, commonly of the chest and abdomen.
• Positron emission tomography combined with CT (PET-CT) uses a small amount of radioactive tracer to highlight areas of activity. It can help clarify limited-stage disease and plan radiotherapy. Inflammation can also show up, so some findings need confirmation.
• Magnetic resonance imaging (MRI) uses a strong magnet and radio waves to make detailed pictures. A brain MRI is important because cancer can be present there without causing symptoms. If MRI is unsuitable, your team will discuss an alternative.

Blood tests check blood cell counts, kidney and liver function, sodium and other substances that affect treatment safety. Symptoms or suspected hormone effects may lead to additional tests. Breathing tests and other checks of general health help plan chest radiotherapy or, occasionally, surgery. The aim is to complete the necessary tests promptly and coordinate your care.

Biomarker tests

Biomarkers are features of cancer cells, such as proteins or gene changes, that can sometimes help guide treatment. Programmed death-ligand 1 (PD-L1) is a protein that can help cancer cells avoid an immune attack. A PD-L1 test is not needed to select the usual first treatment combinations for extensive-stage SCLC. These combine chemotherapy, medicines that kill cancer cells or stop them dividing, with immunotherapy, medicines that help the immune system attack cancer.

Broad gene testing has a more limited role in SCLC than in advanced lung adenocarcinoma, a type of NSCLC. Testing may still help in unusual cases, mixed cancers, transformation or clinical trials (research studies involving patients). Finding a gene change does not automatically mean that a medicine targeting it will help SCLC.

SCLC cells often carry delta-like ligand 3 (DLL3), a protein that tarlatamab targets. Patients who otherwise meet the treatment criteria do not need a DLL3 test before receiving tarlatamab. Your team can explain which tests will guide your treatment and which are being studied in research.

Preparing for your appointment

For your consultation or a second opinion, bring a compact disc (CD) containing your scan images in Digital Imaging and Communications in Medicine (DICOM) format and the software needed to view them. DICOM is the standard format used for medical scans. Bring the written scan reports too. Bring your biopsy report and ask whether the laboratory slides or tissue samples are needed for specialist review or additional tests. Keep originals safe and agree how borrowed material will be returned. Having the actual images allows the team to compare changes and plan treatment accurately.

A repeat test is sometimes needed because an earlier sample was too small, a scan did not cover the necessary area, or a new result will change treatment. Ask what question the test will answer, how it may affect the plan, and when you should expect the result. A result described as uncertain does not automatically mean the cancer is worse. Sometimes discussion between the scan specialist, tissue specialist and treating doctors resolves the uncertainty without another procedure.

Before a scan or procedure, mention kidney problems, previous reactions to contrast dye (used to make scans clearer), implanted devices, diabetes medicines, blood-thinning medicines and the possibility of pregnancy. Follow the testing centre's instructions about food, drink and medicines. If you have not received those instructions, contact the centre rather than making changes yourself.

Planning your treatment

Understanding your stage

TNM ninth-edition staging for small cell lung cancer

TNM combines the main tumour (T), regional lymph nodes (N) and metastasis, or distant spread (M). These findings give a numbered stage. Small cell lung cancer also uses limited and extensive stage to help plan treatment. The diagram shows how the two descriptions fit together.

Lymph nodes are small immune-system structures. Regional nodes are those near or draining the cancer’s starting area; distant spread means cancer has reached a site outside that regional area. Stages describe findings, not a sequence that everyone will pass through.

One cancer, two ways to describe its stage

T · TumourSize and nearby growth

N · NodesSpread to regional lymph nodes

M · MetastasisWhether there is distant spread

TNM stages 1–3 (I–III)

No distant spread · M0

↓

Can the size and location of all the cancer fit safely within a chest radiotherapy plan aimed at a cure?

YesLimited stage

No, it is too widespreadExtensive stage

TNM stage 4 (IV)

Distant spread · M1

↓

Any tumour or node categoryExtensive stage

M1 also includes cancer spread to the opposite lung, cancer deposits or cancerous fluid around the lung or heart, and spread to other organs.

Stages 1–3 are not automatically limited stage. The amount and location of cancer also matter. General health affects treatment choices; it does not by itself change the cancer’s stage.

What each TNM stage means

Stage 1 (I)

A relatively small tumour is in the lung, with no spread to nearby lymph nodes or distant sites. Some limited involvement of nearby lung structures can still fit this stage.

Stage 2 (II)

The tumour is larger, has grown into certain nearby structures, or has spread to a limited number of nearby lymph nodes. There is no distant spread. In the ninth edition, some small tumours with cancer in a single group of lymph nodes between the lungs, on the same side as the tumour, are stage 2.

Stage 3 (III)

There is more extensive growth in the chest, spread to regional lymph nodes, or both, without distant spread. Regional nodes are those near or draining the cancer. Stage 3 includes several patterns; the exact tumour and lymph-node findings determine the subgroup.

Stage 4 (IV)

Cancer involves the opposite lung as a metastasis, cancerous deposits or fluid around the lung or heart, or distant sites such as brain, bone, liver or adrenal glands. Fluid around a lung is not automatically cancerous.

Limited and extensive stage describe the extent of cancer, not how well treatment is working. The detailed TNM stage and your general health also help your team plan treatment.

Clinical stage is based on examinations, biopsies and scans. Examining tissue removed during surgery can add information, called the pathological stage. If the letters yp appear before the stage, the tissue was assessed after treatment. A more complete assessment does not necessarily mean the cancer grew while you were waiting. Grade describes how abnormal the cells look under a microscope and is different from stage.

How your treatment plan is chosen

Your plan depends on the stage, scan findings, symptoms, general health and how well you can tolerate treatment. SCLC can change quickly. Problems such as blocked airways or a dangerously low sodium level may need urgent treatment while the overall plan is completed. Your team should explain what needs to happen promptly and which choices can be discussed in more detail.

For limited-stage disease, chemotherapy and chest radiotherapy are commonly combined with the aim of cure. For extensive-stage disease, treatment that reaches cancer throughout the body (systemic treatment) is central; radiotherapy may help in selected situations. A gentler plan may be appropriate if frailty, reduced organ function or another illness makes intensive treatment unsafe. Age alone should not determine the choice.

Questions specific to small cell lung cancer

• Is the aim to cure the cancer or to control it?
• When should chest radiotherapy start?
• Does the brain MRI show any cancer?
• After the first treatment, would preventive brain radiotherapy or regular brain MRI scans be more suitable for me?
• If immunotherapy is proposed, could a previous organ transplant, steroid medicines or an autoimmune condition affect the choice? Autoimmune conditions occur when the immune system attacks healthy parts of the body.
• Who should I contact urgently between treatment visits?

Understanding response and recurrence

A good early response can improve breathing, appetite and energy, but it does not guarantee that every cancer cell has gone. Scans after the initial treatment help guide the next step. If cancer returns, further choices depend on where it has returned, your current health and the time since your last platinum chemotherapy, such as cisplatin or carboplatin.

A return of cancer is not caused by a lack of positivity or effort. It reflects how the disease behaves. Options may include another medicine, a clinical trial or care focused on comfort and daily life. Ask what benefit the next treatment is likely to offer and what it would involve for you and your caregiver.

Questions to ask your care team

• What is the exact cancer type and stage, and are any important results still pending?
• Is the aim to cure the cancer, reduce the chance of recurrence, control it, or relieve a particular symptom?
• What benefit do you expect from this option, and what are the reasonable alternatives for me?
• How will treatment affect everyday activities, fertility (the ability to have a child), sexual health and the things I most value?
• How will we know whether it is working, and when will we review the plan?
• Who should I contact between visits, including at night or over a weekend?

Clinical trials and newer treatments

A clinical trial can be worth considering at diagnosis or when treatment needs to change. Trials ask a defined question; some compare established treatments and others study a newer approach. Eligibility depends on the cancer, previous treatment, test results and health. Taking part is voluntary, and choosing not to participate does not remove your right to standard care. Ask about extra visits, whether treatment is assigned by chance (randomisation), costs, travel, side effects and what happens when the study ends.

Newer treatments are considered using the clinical evidence, recognised guidelines and the exact cancer type, biomarkers and previous treatment. For some options, the benefits and long-term effects are less certain than for established treatments. Ask what is known, what remains uncertain and whether a clinical trial would be appropriate.

Your priorities and supportive care

Tell the team what you are hoping treatment will make possible: returning to work, caring for family, keeping independence, reducing pain or attending an important event. These priorities can influence a choice between reasonable options. If the likely benefit is small and the burden is substantial, discussing a less intensive approach is appropriate. Decisions can be revisited when your health or circumstances change.

Supportive and palliative care help with symptoms, sleep, mood, family concerns and planning. They can be provided alongside treatment intended to cure or control cancer. A referral does not mean that active treatment is ending. If the cancer cannot be cured, ask what treatments may help you live longer or more comfortably and how their burdens compare with their likely benefits.

Treatment options

Limited-stage treatment with chemotherapy and radiotherapy

For suitable patients, cisplatin or carboplatin is combined with another chemotherapy medicine, etoposide. Chest radiotherapy is given during the same period. This is called concurrent chemoradiotherapy. It can be more effective for suitable patients, but it also increases swallowing problems and other side effects.

Cisplatin and carboplatin have different side effects. Kidney function, hearing, nerve symptoms and general health help guide the choice.

Radiotherapy may be given once or twice daily, depending on the plan. Twice-daily treatment does not simply double the daily dose; the full radiation schedule is designed for this approach. Travel, interruptions and support at home matter. If concurrent treatment is unsuitable, chemotherapy followed by radiotherapy (sequential treatment) or another individual plan may be used.

Treatment after chemoradiotherapy

For eligible adults whose limited-stage SCLC has not grown or spread after concurrent platinum-based chemoradiotherapy, the immunotherapy medicine durvalumab is an established option. This additional treatment is called consolidation therapy. It aims to keep the cancer controlled for longer and help people live longer. It applies to this specific treatment sequence.

Before starting, the team checks your recovery from chemoradiotherapy, lung symptoms and the risk of side effects caused by the immune system attacking healthy tissue. Ask how long treatment will last and when to report symptoms. New breathlessness needs assessment because radiation effects, infection and immunotherapy-related inflammation can cause similar symptoms.

When surgery is considered

Surgery is uncommon in SCLC. It may suit a very early tumour with no lymph-node involvement after careful staging, including checks of the nodes between the lungs (mediastinal nodes). Chemotherapy is normally needed afterwards. Radiotherapy may also be advised, depending on the findings. The decision takes more than whether the tumour looks removable on a scan.

If surgery is unsuitable but the tumour is small and confined to one area, focused radiotherapy may form part of a combined plan. A team specialising in cancers of the chest should review these choices. Treatments used for NSCLC do not automatically suit SCLC.

Extensive-stage first-line treatment

First-line means the first medicine plan used for this stage of the cancer. For many people well enough to receive it, options include carboplatin and etoposide with atezolizumab, or cisplatin or carboplatin and etoposide with durvalumab. These immunotherapy medicines block PD-L1, helping the immune system recognise and attack cancer. A positive PD-L1 test is not required for these standard combinations. Chemotherapy alone may be appropriate if immunotherapy is unsuitable or unavailable.

Treatment can often ease symptoms quickly. It is given in cycles, with treatment followed by time to recover before the next cycle. Blood tests and a review before each cycle check whether it is safe to continue.

After the initial combination, immunotherapy may continue as maintenance treatment to help keep the cancer controlled. Maintenance still has possible side effects. Ask which medicines will continue and how scans will check whether they are helping.

Maintenance treatment after the initial course

Lurbinectedin with atezolizumab is a maintenance option for eligible adults with extensive-stage SCLC that has not grown or spread after initial treatment with atezolizumab, carboplatin and etoposide. This particular sequence has its own risks, especially low blood counts and infection. It does not automatically apply after other first-line combinations or to everyone who has responded.

The maintenance choice depends on your earlier treatment, recovery, likely benefit, side effects and local availability. It can also affect the options if cancer later grows again. Ask your team to explain how each phase of treatment fits into the overall plan.

Brain radiotherapy and regular MRI scans

SCLC has a substantial risk of spreading to the brain. Preventive brain radiotherapy, called prophylactic cranial irradiation (PCI), aims to lower this risk when scans show no cancer in the brain. The choice depends on the stage, response to treatment, age, memory and thinking, MRI findings and ability to attend follow-up scans. Discuss both the possible benefits and the effects on memory and daily life.

For suitable people with extensive-stage disease who respond to treatment, regular brain MRI scans are an important alternative to PCI. This is called MRI surveillance. Scans and prompt treatment for any cancer found in the brain must be reliably available. In limited-stage disease, PCI remains an option after a good response, with particular care when weighing benefits and harms in older or more vulnerable people. Follow-up is needed with either approach.

If cancer has already spread to the brain, treatment aims to control those areas of cancer. It may include radiotherapy to the brain or, in selected cases, precisely focused radiation called stereotactic radiotherapy. The number and location of cancer areas and your overall health help guide the choice. Steroids may be needed to reduce swelling. Cancer in the brain that is causing symptoms needs prompt assessment and treatment.

Other uses of radiotherapy

Some people with extensive-stage disease that responds to medicines may benefit from chest radiotherapy to treat cancer that remains there. The value depends on the spread, response and previous treatment. Radiotherapy can also relieve bone pain, bleeding, blocked airways or pressure caused by a tumour.

Radiotherapy intended to relieve symptoms is called palliative radiotherapy. It may be a short course and can be given alongside medicines that treat cancer throughout the body. Ask when relief is likely and what side effects to expect. A bone at risk of breaking, or pressure on the spinal cord, may need surgical or other specialist treatment as well.

Treatment when cancer returns

Tarlatamab is an option for adults with extensive-stage SCLC that has grown or spread during or after platinum-based chemotherapy. It joins the DLL3 protein on cancer cells to T cells, a type of immune cell, so they can attack the cancer. This is called a bispecific T-cell engager: it connects to two different targets. It works differently from the PD-L1 medicines used in first-line treatment.

Tarlatamab starts with a smaller dose before increasing to the planned dose, with close observation during early treatment. The treatment centre must be equipped to manage serious reactions, including:

• Cytokine release syndrome: a strong immune reaction that can cause fever, low blood pressure and breathing problems.
• Neurological side effects: effects on the brain or nervous system that may cause confusion, difficulty speaking or other changes.

Report these symptoms immediately and follow your centre's emergency instructions. Discuss observation time, travel and caregiver support before treatment starts.

Other options may include topotecan, another chemotherapy combination or a clinical trial. The choice depends on earlier treatments and your health. The US approval for lurbinectedin alone in SCLC progressing after platinum chemotherapy was withdrawn on 30 September 2026. This is separate from its specified maintenance combination with atezolizumab described above. Your team should confirm the current local regulatory position and whether a treatment is appropriate for you. Platinum–etoposide may be used again if the cancer stayed controlled for long enough after the earlier course; your team will assess this individually. Older information mentioning nivolumab or pembrolizumab does not mean these remain routine SCLC treatments.

Choosing further treatment thoughtfully

Further treatment may improve symptoms or delay cancer growth, but the likely benefit often becomes less certain after several treatment plans. Ask what improvement is realistic, how soon to expect it and when treatment would stop if it is not helping. Care focused on comfort and quality of life remains an active choice when further cancer treatment is unlikely to offer enough benefit. Symptom treatment and family support should continue whichever path you choose.

Managing side effects

Swallowing, nutrition and chest symptoms

Chemoradiotherapy can inflame the food pipe and make swallowing painful. Early pain relief, softer foods and advice from a dietitian, a specialist in food and nutrition, can help. Difficulty swallowing fluids, dehydration (too little fluid in the body) or inability to take essential medicines needs urgent contact with your team. A persistent cough or breathlessness after chest treatment also needs assessment.

Chemotherapy and immunotherapy effects

Platinum–etoposide can cause low blood cell counts, nausea, fatigue and hair loss. Low counts can increase the risk of infection, bleeding or anaemia (too few red blood cells to carry oxygen around the body). Cisplatin can affect kidneys, hearing and nerves; carboplatin often has more effects on blood counts. Depending on your treatment, the team may prescribe anti-sickness medicines, fluids or injections to help infection-fighting white blood cells recover. Report ringing in the ears, hearing changes or numbness early.

Immunotherapy can cause inflammation in the lungs, bowel, liver, skin or hormone-producing glands. Symptoms can appear even after treatment stops. Carry your treatment details if you attend another hospital. Report new diarrhoea, marked weakness, yellowing of the eyes or skin (jaundice), unusual thirst or a persistent headache promptly. Symptoms need assessment rather than being assumed to come from the cancer.

Sodium, steroids and symptoms affecting the brain or nerves

Follow your individual plan if sodium is low. Limiting fluids or using other treatments must be supervised by your team. If you take steroids for brain swelling or another reason, follow the prescribed dose and any plan to reduce it gradually (tapering). Stopping suddenly can be unsafe.

Steroids can affect sleep, mood, strength and blood sugar; tell your team about changes. New confusion or weakness needs assessment even if a previous episode had a simple explanation.

Keeping treatment manageable

Keep the team's contact details available and know where to go outside clinic hours. Report side effects early rather than waiting until the next appointment. A short record of symptoms, temperature, fluid intake and medicines can help the team decide what is needed. Do not change cancer medicine doses, restart a stopped treatment, or use leftover antibiotics without instructions. A planned delay or dose adjustment can be an important part of safe treatment.

If you receive treatment that can lower white blood cells, a temperature of 38°C (100.4°F) or higher needs urgent advice. Follow any lower threshold or additional instructions your team gives you. Chills, sudden weakness, confusion or feeling very unwell also need urgent assessment, even without a fever. Do not wait for a blood test appointment or try to hide the fever with medicine before speaking to the team.

Severe breathlessness, chest pain, a new seizure, sudden weakness, heavy bleeding or collapse require emergency care. New severe back pain with leg weakness, numbness around the bottom, or loss of bladder or bowel control also needs immediate assessment. Contact the nearest emergency service when necessary; a website contact form or routine messaging service is not an emergency pathway.

Eating, drinking and energy

Treatment may change appetite, taste, bowel habits and energy. Small, frequent meals and foods containing protein can be easier than large meals. Ask for dietitian support if weight is falling, swallowing is difficult, or you are avoiding many foods. There is no single diet that treats cancer, and severe restriction or prolonged fasting can make it harder to tolerate treatment. Check supplements with your team because some interact with medicines.

Take anti-sickness medicine as prescribed and report vomiting that prevents you keeping down fluids or essential medicines. Seek advice for persistent diarrhoea, dizziness, very little urine or increasing weakness. Fluid recommendations may need adjustment if you have heart or kidney disease. Mouth ulcers, pain or infection that interferes with eating should be treated promptly rather than accepted as unavoidable.

Gentle movement, short walks and planned rest may help fatigue, but activity should match your condition and any surgical or bone-safety restrictions. Fatigue can also reflect anaemia, infection, hormone changes, pain, poor sleep or low mood. Let the team assess a marked or persistent change. Accepting help with shopping, transport or meals can conserve energy for the activities that matter to you.

Live well

Follow-up after treatment

Follow-up commonly includes chest scans and brain MRI. The plan depends on your stage, treatment and whether you had PCI. Visits and scans are usually more frequent early after treatment and change over time. Report symptoms between visits. Cancer that returns can cause different symptoms from the original cancer, so a new persistent symptom deserves attention.

Recovery may involve fatigue, changes in breathing, anxiety about scans or difficulty with memory and concentration. Rehabilitation, which helps you regain strength and daily skills, and emotional support can help. Ask for assessment and practical advice if thinking or memory changes after brain treatment. A companion at appointments and a simple medicine schedule can make daily life easier while supporting independence.

Emotional and practical support

Feeling frightened, angry, sad or uncertain is understandable. You do not have to appear positive all the time. Ask about counselling, specialist emotional support for people with cancer (psycho-oncology), support groups or a social worker if worry is affecting sleep, relationships or daily life. Persistent depression, panic or thoughts of self-harm need prompt professional help. Caregivers may need their own support and breaks; one person should not have to manage every appointment and household task alone.

It can help to agree who will update relatives and how much information you want shared. Children usually benefit from honest, age-appropriate explanations and reassurance about who will care for them. Ask permission before discussing private medical information with others. If concentration or memory is difficult, use reminders, a calendar and a trusted companion at important consultations.

Relationships, fertility and sexual health

Cancer and treatment can affect desire, comfort, fertility, body image and confidence. These are valid medical concerns. Raise fertility questions before treatment when possible, because some protective options need to be arranged early. The right approach depends on age, the treatment and how urgently it must start. Do not assume that absent periods or reduced fertility means pregnancy is impossible. Ask about contraception (preventing pregnancy) and the safe timing of pregnancy for your specific medicines.

Explain any pain, dryness, erection difficulties or changes in intimacy to the team. Appropriate treatments, rehabilitation and counselling can help. You can choose how much to involve a partner. Advice about hormone-containing treatments needs to take the cancer type and treatment into account; do not start them without discussing suitability.

Planning ahead while living well

Ask for a clear follow-up plan and know which symptoms should be reported between visits. Continue care for other conditions and discuss vaccinations with your cancer team. Live vaccines contain weakened germs and may be unsuitable during some treatments. Ask your team which vaccines you can have and when. Avoid tobacco and ask for help to stop smoking if needed. Activity, food and sleep plans should be realistic for your health rather than another source of pressure.

If treatment is long term, arrange periodic discussions about what is helping, what is difficult and what you want next. Planning for future care can protect your preferences and reduce uncertainty for family. You can discuss who should help with decisions if you become too unwell to speak for yourself, while continuing treatment and everyday life now.

Related care

Explore treatments

Medical Oncology↗Ports, PICCs, and venous access↗Cancer Surgery↗Radiation Oncology↗Cancer Diagnostics & Molecular Testing↗Supportive & Holistic Cancer Care↗

Meet our doctors

Dr (Prof) Vijay Agarwal

Professor and Lead Consultant – Medical Oncology

Dr Prathyush V

Senior Consultant – Medical Oncology & Haemato-Oncology

Dr Darshan R S

Consultant – Medical Oncology & Haemato-Oncology

Where to get care

Bannerghatta Road

Apollo Hospitals
Bengaluru

Seshadripuram

Apollo Hospitals
Bengaluru

Sarjapur

Apollo Hospitals
Bengaluru

Jayanagar

Apollo Speciality Hospital
Bengaluru